Up to 10% of patients with metastatic or advanced prostate cancer and 3% of patients with localized prostate cancer carry a disease-causing variant in a DNA repair gene and other genes conferring risk for hereditary cancer disorders.

Invitae’s Detect Hereditary Prostate Cancer is a sponsored, no-charge genetic testing program that uses the Invitae Multi-Cancer Panel. This comprehensive cancer panel tests genes associated with hereditary cancer syndromes, including all known prostate cancer genes.

Determining the germline genetic etiology of prostate cancer provides eligibility for precision medical and surgical treatment options and eligibility to participate in clinical trials. This information can also be used to enable surveillance for, and early detection of, other DNA repair-related cancers in the patient and provide recommendations for early detection in
at­-risk relatives.